Tranzyme Pharma to Report First Quarter 2013 Financial Results
RESEARCH TRIANGLE PARK, N.C., May 2, 2013 (GLOBE NEWSWIRE) -- Tranzyme Pharma
(Nasdaq:TZYM), today announced that the Company will report first quarter 2013
financial results after the close of the market on Thursday, May 9, 2013.
About Tranzyme Pharma
Tranzyme Pharma is a biopharmaceutical company focused on discovering,
developing and commercializing novel, mechanism-based therapeutics. All of
Tranzyme's drug discovery activities are based on its proprietary small
molecule macrocyclic template chemistry (MATCH™) technology, which has also
been successfully used to generate drug candidates in partnership with other
pharmaceutical companies. MATCH enables the rapid construct of synthetic
libraries of drug-like, macrocyclic compounds in a predictable and efficient
manner. By leveraging MATCH, Tranzyme is committed to pursuing first-in-class
medicines to address areas of significant unmet medical need and continues to
pursue funded drug discovery partnerships. Additional information on Tranzyme
can be found at www.tranzyme.com.
Director, Corporate Communications
Press spacebar to pause and continue. Press esc to stop.